2 enrolling by invitation. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol ZEN003694, Enzalutamide - mCRPC | Phase 1 / Phase 2 | Enrolling by invitation | Zenith Epigenetics | 40 | 2019-11-12 | 2026-05-08 |
| Prostate Cancer Patient Management With 18F-DCFPyL PET/CT 18F-DCFPyL PET/CT - Prostate Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Sir Mortimer B. Davis - Jewish General Hospital | 1500 | 2018-06-22 | 2023-11-27 |
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
enzalutamide (1)
Sir Mortimer B. Davis - Jewish General Hospital (1) · Zenith Epigenetics (1)
Canada (1) · United States (1)